AnaptysBio (ANAB) is Initiated by Stifel to “Buy”

AnaptysBio (ANAB) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $30. Stifel advised their Clients and Investors in a research report released on Feb 21, 2017.

Based on several research reports , Credit Suisse Initiated AnaptysBio on Feb 21, 2017 to “Outperform”, Price Target of the shares are set at $34.


Add Comment